From 1 September 2026, specialised accreditation is no longer required for medical practitioners and authorised nurse practitioners to prescribe hepatitis B and hepatitis C medicines accessed through the Pharmaceutical Benefits Scheme (PBS) Section 100 (s100) Highly Specialised Drugs Program.1 Education and training programs for prescribing these medicines will still be available but are no longer mandated.2,3

This change comes after extensive advocacy and consultation and aims to increase timely access to treatment, particularly in regional, rural and remote areas where access to accredited prescribers has been most limited.4

Medical and authorised nurse practitioner prescribers are still required to make sure patient eligibility criteria are met, as per the General Statement for Drugs for the Treatment of Hepatitis C and Treatment of chronic hepatitis B virus infection, and to prescribe within jurisdictional regulations and their scope of practice.2

The World Health Organization has an ongoing commitment to elimination of viral hepatitis as a public health threat5 that is supported by the Australian Government and reflected in the Fourth National Hepatitis B Strategy 2025–2030 and the Sixth National Hepatitis C Strategy 2025–2030. Increasing access to treatment is a key focus of both strategies.

 

Australian Prescriber welcomes Feedback.